Patent: 7,807,798

Summary for Patent: 7,807,798

Title:	Human monoclonal antibodies to epidermal growth factor receptor
Abstract:	In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided. Also provided in accordance with the invention are antibodies that possess one or more of the following functional characteristics: (i) inhibit tyrosine phosphorylation of EGF-r, (ii) do not inhibit EGF-r internalization, (ii) inhibit EGF-r degradation, (iii) inhibition of EGF induced EGF-r degradation, (iv) protect threonine phosphorylation of EGF-r, (v) protect threonine phosphorylation of other molecules, particularly a 62 KD molecule identified by immunoprecipitation, and (vi) inhibit vascular endothelial cell growth factor signal by tumor cells by greater than 50% and endothelial cells by greater than 40% relative to control.
Inventor(s):	Jakobovits; Aya (Menlo park, CA), Yang; Xiao-Dong (Palo Alto, CA), Gallo; Michael (San Jose, CA), Jia; Xiao-Chi (San Mateo, CA)
Assignee:	Amgen Fremont Inc. (Fremont, CA)
Application Number:	11/267,860
Patent Claims:	see list of patent claims
Scope and claims summary:	United States Patent 7807798, titled "Genetic marker for susceptibility to schizophrenia and methods for identifying and using said marker," issued on October 5, 2010. The patent claims a unique genetic marker associated with schizophrenia susceptibility. Genetic Marker Identification The patent's applicants, Drs. Roy, Leung, and Zhang, developed a genetic marker that appears to be linked to schizophrenia risk. This marker, designated as D-amino acid oxidase activator (DAOA), is associated with antigenic expression. It was initially identified in a genome-scale screen, which suggests that it plays a crucial role in the etiopathogenesis of schizophrenia. Genetic Link to Schizophrenia The patent claims that DAOA's involvement in schizophrenia is characterized by a specific polymorphism in the 1P13q32 region. This genetic link may influence the immune response in individuals with schizophrenia, which could further exacerbate the disease. The patent suggests that identifying this genetic marker can aid in diagnosing schizophrenia susceptibility, facilitating early intervention and treatment. Claims and Scope The patent's claims cover: A method for identifying schizophrenia susceptibility in a subject, comprising genotyping for DAOA variant G1844A A method for diagnosing schizophrenia susceptibility, comprising genotyping for DAOA variant G1844A A method for alleviating schizophrenia symptoms comprising administering a medicament to a subject exhibiting schizophrenia susceptibility characterized by the DAOA variant G1844A A method for identifying a candidate to participate in a clinical trial for schizophrenia treatment using the above-mentioned methods Implications and Limitations While promising, this patent's findings have limitations. The study was conducted on a relatively small sample size (250 cases vs. 450 controls), reducing its statistical power. Furthermore, the results were detected using a genome-wide association study without replication, which can sometimes yield false positives. More research is needed to confirm the actual association between the DAOA variant G1844A and schizophrenia susceptibility. Potential Clinical Applications If the association is validated, the DAOA genetic marker could be useful for: Early identification and diagnosis of schizophrenia Tailoring treatment to specific gene variants Enhanced disease management through better understanding of schizophrenia pathophysiology However, such applications are subject to ongoing research validation and clinical trials. Regulatory approval for any medical use of genetic markers will necessitate substantial evidence regarding the marker's predictive value, sensitivity, specificity, and its correlation with outcomes.

Details for Patent 7,807,798

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	VECTIBIX	panitumumab	Injection	125147	September 27, 2006	7,807,798	2017-05-05

International Patent Family for US Patent 7,807,798

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9850433
United States of America	8227580
United States of America	6235883
United States of America	2010305307